Archive WILEX Press Releases

Selected press releases of the former years can be found here.

 2007

18 December 2007

WILEX updates the status of the RENCAREX®* Phase III-ARISER Study following the positive interim analysis for futility

13 December 2007

WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX®*

12 October 2007

WILEX´ second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN

11 October 2007

WILEX Q3 report 2007: progress with development projects – 2007 financial outlook confirmed

01 October 2007

Supervisory Board appoints Thomas Borcholte as Chief Business Officer and member of the Executive Management Board of WILEX AG

24 September 2007

Phase Ib trial with WX-671 in patients with head & neck cancer successfully completed

12 July 2007

WILEX HY1 2007: projects in line with expectations –improved financial outlook

03 July 2007

SAVE THE DATE:
First international symposium on functional and clinical aspects of the tumour antigen CA-IX to be held on 14 November 2007 in Brussels

29 June 2007

WILEX to follow FDA advice and apply for a special protocol assessment (SPA) for CA9-SCAN

26 June 2007

Patient recruitment started in clinical Phase II trial with WX-671 in pancreatic cancer

13 June 2007

Annual General Meeting appoints new Supervisory Board Members

13 April 2007

WILEX publishes Q1 2007 figures - results in line with expectations

03 April 2007

WILEX gives positive update of current pivotal Phase III trial of RENCAREX®*

27 February 2007

WILEX reports a successfull financial year 2006 – positive outlook and guidance 2007

 2006

 2005

 2004

 2003

 2002 and earlier